Market Research

Diabetic Neuropathy Market (Disorder Type: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy; and Treatment Type: Drugs, Radiotherapy, and Physiotherapy) - Global Industry Analysis, Size, Share, Growth, Trends, and For

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 251 Pages Transparency Market Research Pvt. Ltd. April, 2024 TNPR18827849
Best Price Guarantee
Price from $5,795
Length 251 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date April, 2024
SKU TNPR18827849

Diabetic Neuropathy Market (Disorder Type: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy; and Treatment Type: Drugs, Radiotherapy, and Physiotherapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


Diabetic Neuropathy Market – Scope of Report

TMR’s report on the global diabetic neuropathy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global diabetic neuropathy market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global diabetic neuropathy market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the diabetic neuropathy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global diabetic neuropathy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global diabetic neuropathy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global diabetic neuropathy market.

The report delves into the competitive landscape of the global diabetic neuropathy market. Key players operating in the global diabetic neuropathy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global diabetic neuropathy market profiled in this report.

Key Questions Answered in Global diabetic neuropathy Market Report
  • What is the sales/revenue generated by diabetic neuropathy across all regions during the forecast period?
  • What are the opportunities in the global diabetic neuropathy market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Diabetic Neuropathy Market – Research Objectives and Research Approach

The comprehensive report on the global diabetic neuropathy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global diabetic neuropathy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global diabetic neuropathy market.


1. Preface
  1.1. Market Definition and Scope
  1.2. Market Segmentation
  1.3. Key Research Objectives
  1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Diabetic Neuropathy Market
4. Market Overview
  4.1. Introduction
  4.1.1. Product Definition
  4.1.2. Industry Evolution/Developments
  4.2. Overview
  4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunities
  4.4. Diabetic Neuropathy Market Analysis and Forecast, 2020-2034
5. Key Insights
  5.1. Pipeline Analysis
  5.2. Key Product /Brand Analysis
  5.3. Key Mergers & Acquisitions
  5.4. COVID-19 Pandemic Impact on Industry
6. Global Diabetic Neuropathy Market Analysis and Forecast, by Disorder Type
  6.1. Introduction & Definition
  6.2. Key Findings/Developments
  6.3. Market Value Forecast, by Disorder Type, 2020-2034
  6.3.1. Peripheral Neuropathy
  6.3.2. Autonomic Neuropathy
  6.3.3. Proximal Neuropathy
  6.3.4. Focal Neuropathy
  6.4. Market Attractiveness Analysis, by Disorder Type
7. Global Diabetic Neuropathy Market Analysis and Forecast, by Treatment Type
  7.1. Introduction & Definition
  7.2. Key Findings/Developments
  7.3. Market Value Forecast, by Treatment Type, 2020-2034
  7.3.1. Drugs
  7.3.1.1. Analgesics
  7.3.1.1.1. Topical
  7.3.1.1.1.1. Capsaicin
  7.3.1.1.1.2. Others
  7.3.1.1.2. Opioids
  7.3.1.1.2.1. Morphine
  7.3.1.1.2.2. Others
  7.3.1.1.3. NSAIDs
  7.3.1.1.3.1. Ibuprofen
  7.3.1.1.3.2. Naproxen
  7.3.1.1.3.3. Others
  7.3.1.2. Antidepressants
  7.3.1.2.1. TCAs
  7.3.1.2.1.1. Amitriptyline
  7.3.1.2.1.2. Imipramine
  7.3.1.2.1.3. Others
  7.3.1.2.2. SNRIs
  7.3.1.2.2.1. Duloxetine
  7.3.1.2.2.2. Others
  7.3.1.2.3. SSRIs
  7.3.1.2.3.1. Citalopram
  7.3.1.2.3.2. Paroxetin
  7.3.1.2.3.3. Others
  7.3.1.3. Anticonvulsants
  7.3.1.3.1. Gabapentin
  7.3.1.3.2. Pregabalin
  7.3.1.3.3. Topimarate
  7.3.1.3.4. Others
  7.3.1.4. Other Drugs
  7.3.2. Radiotherapy
  7.3.2.1. TENS
  7.3.2.2. Others
  7.3.3. Physiotherapy
  7.4. Market Attractiveness Analysis, by Treatment Type
8. Global Diabetic Neuropathy Market Analysis and Forecast, by Distribution Channel
  8.1. Introduction & Definition
  8.2. Key Findings/Developments
  8.3. Market Value Forecast, by Distribution Channel, 2020-2034
  8.3.1. Hospitals
  8.3.2. Clinics
  8.3.3. Retail Pharmacies
  8.3.4. Online Pharmacies
  8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Diabetic Neuropathy Market Analysis and Forecast, by Region
  9.1. Key Findings
  9.2. Market Value Forecast, by Region, 2020-2034
  9.2.1. North America
  9.2.2. Europe
  9.2.3. Asia Pacific
  9.2.4. Latin America
  9.2.5. Middle East & Africa
  9.3. Market Attractiveness Analysis, by Region
10. North America Diabetic Neuropathy Market Analysis and Forecast
  10.1. Introduction
  10.2. Key Findings
  10.3. Market Value Forecast, by Disorder Type, 2020-2034
  10.3.1. Peripheral Neuropathy
  10.3.2. Autonomic Neuropathy
  10.3.3. Proximal Neuropathy
  10.3.4. Focal Neuropathy
  10.4. Market Value Forecast, by Treatment Type, 2020-2034
  10.4.1. Drugs
  10.4.1.1. Analgesics
  10.4.1.1.1. Topical
  10.4.1.1.1.1. Capsaicin
  10.4.1.1.1.2. Others
  10.4.1.1.2. Opioids
  10.4.1.1.2.1. Morphine
  10.4.1.1.2.2. Others
  10.4.1.1.3. NSAIDs
  10.4.1.1.3.1. Ibuprofen
  10.4.1.1.3.2. Naproxen
  10.4.1.1.3.3. Others
  10.4.1.2. Antidepressants
  10.4.1.2.1. TCAs
  10.4.1.2.1.1. Amitriptyline
  10.4.1.2.1.2. Imipramine
  10.4.1.2.1.3. Others
  10.4.1.2.2. SNRIs
  10.4.1.2.2.1. Duloxetine
  10.4.1.2.2.2. Others
  10.4.1.2.3. SSRIs
  10.4.1.2.3.1. Citalopram
  10.4.1.2.3.2. Paroxetin
  10.4.1.2.3.3. Others
  10.4.1.3. Anticonvulsants
  10.4.1.3.1. Gabapentin
  10.4.1.3.2. Pregabalin
  10.4.1.3.3. Topimarate
  10.4.1.3.4. Others
  10.4.1.4. Other Drugs
  10.4.2. Radiotherapy
  10.4.2.1. TENS
  10.4.2.2. Others
  10.4.3. Physiotherapy
  10.5. Market Value Forecast, by Distribution Channel, 2020-2034
  10.5.1. Hospitals
  10.5.2. Clinics
  10.5.3. Retail Pharmacies
  10.5.4. Online Pharmacies
  10.6. Market Value Forecast, by Country, 2020-2034
  10.6.1. U.S.
  10.6.2. Canada
  10.7. Market Attractiveness Analysis
  10.7.1. By Disorder Type
  10.7.2. By Treatment Type
  10.7.3. By Distribution Channel
  10.7.4. By Country
11. Europe Diabetic Neuropathy Market Analysis and Forecast
  11.1. Introduction
  11.2. Key Findings
  11.3. Market Value Forecast, by Disorder Type, 2020-2034
  11.3.1. Peripheral Neuropathy
  11.3.2. Autonomic Neuropathy
  11.3.3. Proximal Neuropathy
  11.3.4. Focal Neuropathy
  11.4. Market Value Forecast, by Treatment Type, 2020-2034
  11.4.1. Drugs
  11.4.1.1. Analgesics
  11.4.1.1.1. Topical
  11.4.1.1.1.1. Capsaicin
  11.4.1.1.1.2. Others
  11.4.1.1.2. Opioids
  11.4.1.1.2.1. Morphine
  11.4.1.1.2.2. Others
  11.4.1.1.3. NSAIDs
  11.4.1.1.3.1. Ibuprofen
  11.4.1.1.3.2. Naproxen
  11.4.1.1.3.3. Others
  11.4.1.2. Antidepressants
  11.4.1.2.1. TCAs
  11.4.1.2.1.1. Amitriptyline
  11.4.1.2.1.2. Imipramine
  11.4.1.2.1.3. Others
  11.4.1.2.2. SNRIs
  11.4.1.2.2.1. Duloxetine
  11.4.1.2.2.2. Others
  11.4.1.2.3. SSRIs
  11.4.1.2.3.1. Citalopram
  11.4.1.2.3.2. Paroxetin
  11.4.1.2.3.3. Others
  11.4.1.3. Anticonvulsants
  11.4.1.3.1. Gabapentin
  11.4.1.3.2. Pregabalin
  11.4.1.3.3. Topimarate
  11.4.1.3.4. Others
  11.4.1.4. Other Drugs
  11.4.2. Radiotherapy
  11.4.2.1. TENS
  11.4.2.2. Others
  11.4.3. Physiotherapy
  11.5. Market Value Forecast, by Distribution Channel, 2020-2034
  11.5.1. Hospitals
  11.5.2. Clinics
  11.5.3. Retail Pharmacies
  11.5.4. Online Pharmacies
  11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  11.6.1. Germany
  11.6.2. U.K.
  11.6.3. France
  11.6.4. Italy
  11.6.5. Spain
  11.6.6. Rest of Europe
  11.7. Market Attractiveness Analysis
  11.7.1. By Disorder Type
  11.7.2. By Treatment Type
  11.7.3. By Distribution Channel
  11.7.4. By Country/Sub-region
12. Asia Pacific Diabetic Neuropathy Market Analysis and Forecast
  12.1. Introduction
  12.2. Key Findings
  12.3. Market Value Forecast, by Disorder Type, 2020-2034
  12.3.1. Peripheral Neuropathy
  12.3.2. Autonomic Neuropathy
  12.3.3. Proximal Neuropathy
  12.3.4. Focal Neuropathy
  12.4. Market Value Forecast, by Treatment Type, 2020-2034
  12.4.1. Drugs
  12.4.1.1. Analgesics
  12.4.1.1.1. Topical
  12.4.1.1.1.1. Capsaicin
  12.4.1.1.1.2. Others
  12.4.1.1.2. Opioids
  12.4.1.1.2.1. Morphine
  12.4.1.1.2.2. Others
  12.4.1.1.3. NSAIDs
  12.4.1.1.3.1. Ibuprofen
  12.4.1.1.3.2. Naproxen
  12.4.1.1.3.3. Others
  12.4.1.2. Antidepressants
  12.4.1.2.1. TCAs
  12.4.1.2.1.1. Amitriptyline
  12.4.1.2.1.2. Imipramine
  12.4.1.2.1.3. Others
  12.4.1.2.2. SNRIs
  12.4.1.2.2.1. Duloxetine
  12.4.1.2.2.2. Others
  12.4.1.2.3. SSRIs
  12.4.1.2.3.1. Citalopram
  12.4.1.2.3.2. Paroxetin
  12.4.1.2.3.3. Others
  12.4.1.3. Anticonvulsants
  12.4.1.3.1. Gabapentin
  12.4.1.3.2. Pregabalin
  12.4.1.3.3. Topimarate
  12.4.1.3.4. Others
  12.4.1.4. Other Drugs
  12.4.2. Radiotherapy
  12.4.2.1. TENS
  12.4.2.2. Others
  12.4.3. Physiotherapy
  12.5. Market Value Forecast, by Distribution Channel, 2020-2034
  12.5.1. Hospitals
  12.5.2. Clinics
  12.5.3. Retail Pharmacies
  12.5.4. Online Pharmacies
  12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  12.6.1. China
  12.6.2. Japan
  12.6.3. India
  12.6.4. Australia & New Zealand
  12.6.5. Rest of Asia Pacific
  12.7. Market Attractiveness Analysis
  12.7.1. By Disorder Type
  12.7.2. By Treatment Type
  12.7.3. By Distribution Channel
  12.7.4. By Country/Sub-region
13. Latin America Diabetic Neuropathy Market Analysis and Forecast
  13.1. Introduction
  13.2. Key Findings
  13.3. Market Value Forecast, by Disorder Type, 2020-2034
  13.3.1. Peripheral Neuropathy
  13.3.2. Autonomic Neuropathy
  13.3.3. Proximal Neuropathy
  13.3.4. Focal Neuropathy
  13.4. Market Value Forecast, by Treatment Type, 2020-2034
  13.4.1. Drugs
  13.4.1.1. Analgesics
  13.4.1.1.1. Topical
  13.4.1.1.1.1. Capsaicin
  13.4.1.1.1.2. Others
  13.4.1.1.2. Opioids
  13.4.1.1.2.1. Morphine
  13.4.1.1.2.2. Others
  13.4.1.1.3. NSAIDs
  13.4.1.1.3.1. Ibuprofen
  13.4.1.1.3.2. Naproxen
  13.4.1.1.3.3. Others
  13.4.1.2. Antidepressants
  13.4.1.2.1. TCAs
  13.4.1.2.1.1. Amitriptyline
  13.4.1.2.1.2. Imipramine
  13.4.1.2.1.3. Others
  13.4.1.2.2. SNRIs
  13.4.1.2.2.1. Duloxetine
  13.4.1.2.2.2. Others
  13.4.1.2.3. SSRIs
  13.4.1.2.3.1. Citalopram
  13.4.1.2.3.2. Paroxetin
  13.4.1.2.3.3. Others
  13.4.1.3. Anticonvulsants
  13.4.1.3.1. Gabapentin
  13.4.1.3.2. Pregabalin
  13.4.1.3.3. Topimarate
  13.4.1.3.4. Others
  13.4.1.4. Other Drugs
  13.4.2. Radiotherapy
  13.4.2.1. TENS
  13.4.2.2. Others
  13.4.3. Physiotherapy
  13.5. Market Value Forecast, by Distribution Channel, 2020-2034
  13.5.1. Hospitals
  13.5.2. Clinics
  13.5.3. Retail Pharmacies
  13.5.4. Online Pharmacies
  13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  13.6.1. Brazil
  13.6.2. Mexico
  13.6.3. Rest of Latin America
  13.7. Market Attractiveness Analysis
  13.7.1. By Disorder Type
  13.7.2. By Treatment Type
  13.7.3. By Distribution Channel
  13.7.4. By Country/Sub-region
14. Middle East & Africa Diabetic Neuropathy Market Analysis and Forecast
  14.1. Introduction
  14.2. Key Findings
  14.3. Market Value Forecast, by Disorder Type, 2020-2034
  14.3.1. Peripheral Neuropathy
  14.3.2. Autonomic Neuropathy
  14.3.3. Proximal Neuropathy
  14.3.4. Focal Neuropathy
  14.4. Market Value Forecast, by Treatment Type, 2020-2034
  14.4.1. Drugs
  14.4.1.1. Analgesics
  14.4.1.1.1. Topical
  14.4.1.1.1.1. Capsaicin
  14.4.1.1.1.2. Others
  14.4.1.1.2. Opioids
  14.4.1.1.2.1. Morphine
  14.4.1.1.2.2. Others
  14.4.1.1.3. NSAIDs
  14.4.1.1.3.1. Ibuprofen
  14.4.1.1.3.2. Naproxen
  14.4.1.1.3.3. Others
  14.4.1.2. Antidepressants
  14.4.1.2.1. TCAs
  14.4.1.2.1.1. Amitriptyline
  14.4.1.2.1.2. Imipramine
  14.4.1.2.1.3. Others
  14.4.1.2.2. SNRIs
  14.4.1.2.2.1. Duloxetine
  14.4.1.2.2.2. Others
  14.4.1.2.3. SSRIs
  14.4.1.2.3.1. Citalopram
  14.4.1.2.3.2. Paroxetin
  14.4.1.2.3.3. Others
  14.4.1.3. Anticonvulsants
  14.4.1.3.1. Gabapentin
  14.4.1.3.2. Pregabalin
  14.4.1.3.3. Topimarate
  14.4.1.3.4. Others
  14.4.1.4. Other Drugs
  14.4.2. Radiotherapy
  14.4.2.1. TENS
  14.4.2.2. Others
  14.4.3. Physiotherapy
  14.5. Market Value Forecast, by Distribution Channel, 2020-2034
  14.5.1. Hospitals
  14.5.2. Clinics
  14.5.3. Retail Pharmacies
  14.5.4. Online Pharmacies
  14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  14.6.1. GCC Countries
  14.6.2. South Africa
  14.6.3. Rest of Middle East & Africa
  14.7. Market Attractiveness Analysis
  14.7.1. By Disorder Type
  14.7.2. By Treatment Type
  14.7.3. By Distribution Channel
  14.7.4. By Country/Sub-region
15. Competition Landscape
  15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  15.2. Market Share Analysis, by Company (2023)
  15.3. Company Profiles
  15.3.1. Johnson & Johnson (Janssen Global Services, LLC)
  15.3.1.1. Company Overview
  15.3.1.2. Product Portfolio
  15.3.1.3. SWOT Analysis
  15.3.1.4. Financial Overview
  15.3.1.5. Strategic Overview
  15.3.2. Boehringer Ingelheim GmbH
  15.3.2.1. Company Overview
  15.3.2.2. Product Portfolio
  15.3.2.3. SWOT Analysis
  15.3.2.4. Financial Overview
  15.3.2.5. Strategic Overview
  15.3.3. NeuroMetrix, Inc.
  15.3.3.1. Company Overview
  15.3.3.2. Product Portfolio
  15.3.3.3. SWOT Analysis
  15.3.3.4. Financial Overview
  15.3.3.5. Strategic Overview
  15.3.4. Eli Lilly and Company
  15.3.4.1. Company Overview
  15.3.4.2. Product Portfolio
  15.3.4.3. SWOT Analysis
  15.3.4.4. Financial Overview
  15.3.4.5. Strategic Overview
  15.3.5. GlaxoSmithKline plc
  15.3.5.1. Company Overview
  15.3.5.2. Product Portfolio
  15.3.5.3. SWOT Analysis
  15.3.5.4. Financial Overview
  15.3.5.5. Strategic Overview
  15.3.6. Lupin Limited
  15.3.6.1. Company Overview
  15.3.6.2. Product Portfolio
  15.3.6.3. SWOT Analysis
  15.3.6.4. Financial Overview
  15.3.6.5. Strategic Overview
  15.3.7. Pfizer Inc.
  15.3.7.1. Company Overview
  15.3.7.2. Product Portfolio
  15.3.7.3. SWOT Analysis
  15.3.7.4. Financial Overview
  15.3.7.5. Strategic Overview
  15.3.8. Astellas Pharma Inc.
  15.3.8.1. Company Overview
  15.3.8.2. Product Portfolio
  15.3.8.3. SWOT Analysis
  15.3.8.4. Financial Overview
  15.3.8.5. Strategic Overview
  15.3.9. Glenmark Pharmaceuticals Ltd.
  15.3.9.1. Company Overview
  15.3.9.2. Product Portfolio
  15.3.9.3. SWOT Analysis
  15.3.9.4. Financial Overview
  15.3.9.5. Strategic Overview
  15.3.10. Arbor Pharmaceuticals, LLC
  15.3.10.1. Company Overview
  15.3.10.2. Product Portfolio
  15.3.10.3. SWOT Analysis
  15.3.10.4. Financial Overview
  15.3.10.5. Strategic Overview
  15.3.11. Depomed, Inc.
  15.3.11.1. Company Overview
  15.3.11.2. Product Portfolio
  15.3.11.3. SWOT Analysis
  15.3.11.4. Financial Overview
  15.3.11.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings